pSivida Corp
(ASX:PVA) has announced that it plans to file for EU marketing approval for Medidur, a drug that treats eye disease.
The company says that based on positive efficacy and safety data from its first trial it will meet the criteria to approve the product.
The eye disease known as Posterior Uveitis, which can cause blindness, affects a similar amount of people in the US and Europe.
The company plans to file for European Approval in the second half of 2016.
pSivida reported a net profit of $8.26 million at 30 June 2015.
